Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent ...

US clinical-stage pharma company Protagonist Therapeutics and Japan’s Takeda have announced positive top-line results for the ...

JPMorgan raised the firm’s price target on Protagonist Therapeutics (PTGX) to $57 from $53 and keeps an Overweight rating on the shares. The ...

The former Major League Baseball star spent 16 seasons with the Chicago White Sox and Detroit Tigers before coaching in ...

The live webcast for each event will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presentations” tab. Replays of the webcasts will be archived on ...

Bank of New York Mellon Corp boosted its position in Incyte Co. (NASDAQ:INCY – Free Report) by 7.5% in the 4th quarter, ...

HC Wainwright restated their buy rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research report released on Monday morning,Benzinga reports. They currently have a $54.00 ...

Blood clotting disorders can be inherited or acquired. Some types cause excessive bleeding, while others cause excessive ...